Maxim Group Maintains ‘Buy’ Rating On Tekmira Pharmaceuticals (TKMR)

Analysts at Maxim Group maintained their ‘Buy’ rating and $23.00 price target on the shares of Tekmira Pharmaceuticals Corp (TKMR) in a research report issued to clients and investors on Monday. Maxim notes that the recent outbreak of Ebola has renewed hope that a trial of the company’s TKM-Ebola project, which has shown 100% efficacy […] View the full post at: Maxim Group Maintains ‘Buy’ Rating On Tekmira Pharmaceuticals (TKMR) Related posts: Moody’s Downgrades Greece’s Debt Rating to A2 BofA Needs $35 Billion in Additional Capital Weekly Initial Unemployment Claims at 456K